Reclast (Zoledronic Acid) and Sildenafil Interaction: Safety, Risks, and Clinical Guidance

Why This Combination Comes Up

Zoledronic acid (Reclast) is a once-yearly intravenous bisphosphonate used for osteoporosis and Paget disease. Sildenafil (Viagra) is an on-demand oral PDE5 inhibitor for erectile dysfunction. Both are common in the same population: osteoporosis is well documented in men, particularly with advancing age [1], and erectile dysfunction is common in the same age range, with the Massachusetts Male Aging Study finding it present to some degree in roughly half of men surveyed between ages 40 and 70 (N=1,290) [2].

Because Reclast is infused only once a year, the calendar time during which both drugs are active in the body at once is small. What matters clinically is not that a man takes both drugs over the course of a year, but whether he takes sildenafil during the narrow window right around an infusion, when the acute phase reaction can be underway.

No Metabolic Overlap

Zoledronic acid is not metabolized by the liver. Based on general pharmacology, it is not thought to be a substrate, inhibitor, or inducer of cytochrome P450 enzymes; it circulates largely unbound, binds to bone mineral, and is understood to be cleared renally. Sildenafil, by contrast, is metabolized primarily through CYP3A4, with a secondary contribution from CYP2C9. Because zoledronic acid does not touch this pathway, there is no basis for a pharmacokinetic interaction: no competition for the same enzyme, no change in sildenafil's blood levels, and no need for a dose adjustment on metabolic grounds.

This is the most reassuring part of the interaction picture, and it is well supported by both labels. It is also the part most databases are built to flag, which is one reason this pair does not appear as a rated interaction in standard checkers.

The Real Question: Overlapping Blood Pressure Effects

Sildenafil inhibits phosphodiesterase type 5 in vascular smooth muscle, increasing cyclic GMP and producing vasodilation. Sildenafil's prescribing information reports a mean maximal decrease in supine blood pressure of about 8.4 mmHg systolic and 5.5 mmHg diastolic after a single 100 mg dose, typically without symptoms in healthy men, but with a specific contraindication against nitrates and a caution about alpha-blockers.

Zoledronic acid does not act on the same vascular pathway. Its blood pressure effects, when they occur, are tied to the acute phase reaction: a systemic inflammatory response in the first one to three days after infusion, thought to involve activation of gamma-delta T cells and release of cytokines such as IL-6 and TNF-alpha [5]. During this window some patients develop fever, myalgia, and transient hemodynamic changes. The pivotal HORIZON Pivotal Fracture Trial reported acute phase reaction symptoms, including fever, in a substantial minority of patients after the first infusion, with the rate dropping markedly on repeat annual doses [6].

Published trial data do not give a precise, verified incidence figure specifically for clinically significant hypotension attributable to the acute phase reaction alone, as distinct from fever and myalgia. A reviewing clinician or pharmacist should check the primary HORIZON publications and the current FDA label directly before citing a specific hypotension rate to a patient; this article intentionally does not state one [6].

Evidence-Status Interaction Assessment

Before advising a specific patient, a reviewing clinician or pharmacist should independently confirm each "not established" row against current primary sources rather than relying on this table alone.

What the Databases Actually Say

Checking standard interaction resources for this review did not surface a dedicated pharmacokinetic interaction entry for zoledronic acid and sildenafil, consistent with the lack of shared metabolic pathway. A general clinical pharmacology overview of bisphosphonate use is available through the NCBI Bookshelf [7]. Neither the Endocrine Society's guideline on osteoporosis in men [8] nor the AACE/ACE 2020 postmenopausal osteoporosis guideline [9] lists PDE5 inhibitors as requiring dose modification alongside bisphosphonate therapy.

The absence of a flagged interaction is consistent with the pharmacology described above. It does not by itself prove the combination is risk-free in every patient; it means the concern is timing-dependent and has not been the subject of dedicated study, not that it has been studied and cleared.

The Acute Phase Reaction Window

Understanding the acute phase reaction timeline is the practical key to this interaction. In the HORIZON Pivotal Fracture Trial, acute phase symptoms were most common after the first infusion and clearly less common on repeat annual doses, with fever being the most frequently reported individual symptom [6]. Symptoms generally began within a day of infusion and resolved within about three days.

Pretreatment with acetaminophen around the time of infusion has been shown in a randomized trial to reduce the incidence of post-dose symptoms [10]. This does not eliminate the acute phase reaction but supports the general practice of offering pretreatment, especially before a first infusion.

For a patient taking sildenafil, the practical takeaway is that the period of overlap worth planning around is the first few days after infusion, particularly the first infusion a patient receives, rather than the rest of the year in between doses.

Monitoring and Practical Precautions

Before infusion: document baseline blood pressure, all current medications including PDE5 inhibitors and antihypertensives, and any history of orthostatic hypotension. Confirm renal function meets the threshold required for zoledronic acid use, since the drug is contraindicated at low creatinine clearance.

On infusion day: a reasonable, pragmatic approach is to avoid new sildenafil dosing on the day of infusion and while any acute phase symptoms (fever, myalgia, lightheadedness) are present. This is a precaution based on the mechanism and timeline described above, not a labeled requirement from either drug's prescribing information, and should be individualized.

After infusion: if a patient develops fever, myalgia, or feels lightheaded in the days following infusion, holding sildenafil until symptoms resolve is a reasonable default, with closer attention for patients also taking antihypertensives or alpha-blockers.

Dosing: No Established Adjustment

Neither drug's prescribing information requires a dose change based on co-administration with the other drug. Zoledronic acid dosing is fixed at 5 mg IV, given once annually for osteoporosis or as a single dose for Paget disease. Sildenafil dosing for erectile dysfunction ranges from 25 to 100 mg as needed, with a 25 mg starting dose recommended for patients over 65 or those with significant hepatic or renal impairment, or those on strong CYP3A4 inhibitors. Because zoledronic acid does not affect CYP3A4, it does not trigger this lower-dose recommendation on its own.

Populations Warranting Closer Attention

Men on alpha-blockers: sildenafil's prescribing information already carries a caution about co-administration with alpha-1 blockers (used for benign prostatic hyperplasia), recommending a 25 mg starting dose in that setting. Adding a period of possible post-infusion hemodynamic change is a reasonable additional reason for caution, though it has not been studied as a three-way interaction.

Patients with renal impairment: zoledronic acid is contraindicated below a creatinine clearance threshold specified in its prescribing information. Sildenafil clearance is also reduced with significant renal impairment, which can raise plasma levels and blood pressure effects. Patients near the overlap of these thresholds warrant individualized review rather than a generic rule.

Patients on multiple antihypertensives: sildenafil's blood-pressure-lowering effect is generally understood to be more pronounced in patients already on antihypertensive therapy, based on general pharmacology. A precise combined-effect number for this population plus a recent zoledronic acid infusion has not been established and should not be quoted as a fixed figure.

Patients with a prior significant acute phase reaction: men who had marked fever, rigors, or hypotension after a previous infusion are reasonable candidates for pretreatment and a longer post-infusion observation period before resuming sildenafil [10].

Patients on sildenafil for pulmonary arterial hypertension (Revatio): this population takes sildenafil on a fixed schedule rather than as needed. Abrupt discontinuation of PDE5 inhibitor therapy in pulmonary arterial hypertension carries its own hemodynamic risk and should not be done without involving the prescribing specialist [11]. Any adjustment around a Reclast infusion in this population should be coordinated with that specialist rather than decided unilaterally.

What the Evidence Does Not Show

A search of the primary literature did not surface a published case report describing a serious adverse event specific to the combination of zoledronic acid and sildenafil. General background on the FDA Adverse Event Reporting System, including how to search its public dashboard for a given drug pair, is available directly from the FDA. A reviewing pharmacist should run that search directly rather than relying on this article's characterization of it, since a text-based literature review is not equivalent to a live database query.

Absence of a published report is consistent with the pharmacology described here, but it is not the same as proof of safety across all patients and circumstances, particularly for a combination that would not necessarily generate a distinctive, easily searchable adverse event signal.

Patient Counseling Points

• You can generally continue sildenafil use. The concern is specifically about timing it near a Reclast infusion, not about using the two drugs over the course of a year.
• Consider avoiding sildenafil on the day of infusion and while you have fever, muscle aches, or other flu-like symptoms afterward, and resume once those resolve.
• Stay hydrated before and after the infusion, consistent with your infusion center's instructions.
• If you feel dizzy or lightheaded standing up in the days after infusion, sit down, rehydrate, and contact your provider before taking sildenafil again.
• If you take sildenafil on a fixed schedule for pulmonary arterial hypertension, do not stop or adjust it around your infusion without talking to the physician who prescribes it for that condition.